Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
PremiumPress ReleasesMerus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
2M ago
Merus announces first patient dosed in LiGeR-HN2 trial
Premium
The Fly
Merus announces first patient dosed in LiGeR-HN2 trial
2M ago
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Premium
Press Releases
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
2M ago
Merus price target raised to $93 from $70 at Citi
PremiumThe FlyMerus price target raised to $93 from $70 at Citi
3M ago
Xevinapant’s discontinuation reads positive for Merus, says BofA
Premium
The Fly
Xevinapant’s discontinuation reads positive for Merus, says BofA
3M ago
Merus price target raised to $99 from $90 at Stifel
Premium
The Fly
Merus price target raised to $99 from $90 at Stifel
3M ago
Merus price target raised to $67 from $54 at Canaccord
PremiumThe FlyMerus price target raised to $67 from $54 at Canaccord
4M ago
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
Premium
Press Releases
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
4M ago
Merus presents interim data on MCLA-145 monotherapy, combo with pembrolizumab
Premium
The Fly
Merus presents interim data on MCLA-145 monotherapy, combo with pembrolizumab
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100